Interactions between actos(pioglitazone) and Dasatinib (dasatinib)
pioglitazone and dasatinib (Moderate Drug-Drug)
MONITOR: Coadministration with dasatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dasatinib, which is a time-dependent inhibitor of the isoenzyme. In a pharmacokinetic study of 54 healthy subjects, administration of simvastatin with a single 100 mg dose of dasatinib increased the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of simvastatin by 37% and 20%, respectively, compared to administration without dasatinib.
MANAGEMENT: Caution is advised if dasatinib must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dasatinib is added to or withdrawn from therapy.
